Professor Zhang Qingxuan interview: From lymphoma to breast cancer, HDAC inhibitor Sidabenamine has a breakthrough in solid tumors

Sidabenamine is the first epigenetic regulatory drug with China's independent intellectual property rights, approved five years ago to treat lymphoma, has caused a sensation in the industryBased on the ACE study, the National Drug Administration (NMPA) again approved sidabenamine combined aromatase inhibitors for the treatment of advanced breast cancer, and the 2020 edition of the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnostic Guidelines also listed the Sidabenamine Joint Program TAM as a treatment failure and an I.-grade recommendation for nonsteroidal AI treatment failure (evidence level 1A) in the latest updaterecommended by the guidelines for the original Chinese new drug Sidabenaminei am very lucky to be involved in the critical study of Sidabenamine for the treatment of lymphoma and breast cancerSidabenamine is the first epigenetic regulatory drug with complete Chinese independent intellectual property rights, is HDAC inhibitor, the efficacy in lymphoma, especially T-cell lymphoma is very prominent, T-cell lymphoma is a relatively high incidence of lymphoma type in Asia, the current lack of good treatment, the emergence of Sidabenamine undoubtedly brought the gospel to the vast number of peripheral T-cell lymphoma patients, 5 years ago CFDA approved sidabenlyslympen lymphoma treatmentSidabenamine as an epigenetic regulatory drug in breast cancer treatment also has a stunning performance, we carried out the ACE study for hormone-receptor-positive HER2-negative breast cancer, with the endocrine drug is isimatoran treatment of this highest incidence of breast cancer type, but also achieved very good resultsAlthough there are many endocrine-targeted drugs, such as CDK4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors, drug resistance and toxic side effects of combination therapy have also been plagued by clinical workThe combination of Sidabenamine and endocrine therapy not only achieved good results, but also greatly enriched the choice of endocrine therapy for breast cancer, and the patient's tolerance was very goodAt present, China's NMPA has approved sidabenamine combined aromatase inhibitors for the treatment of hormone receptor-positive HER2-negative breast cancer, to improve the survival of breast cancer patients in China with a major helpin addition, according to the new Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines, released on April 10, the Expert Group recommends: (1) For patients with HR-advanced postmenopausal breast cancer, the Expert Group recommends: (1) for patients with patients who fail to treat tamoxifen, the new HDAC inhibitor combined AI program is recommended for I.-level (evidence level 1A) ;(2) for patients with nonsteroidal AI treatment failure, HDAC AIIt is believed that with the recommended level of Sidabenamine and the renewal of the evidence level, the drug accessibility will be reshuffled, and patients with HR-advanced breast cancer will have a more diverse treatment optionACE research uses strength to demonstrate the remarkable efficacy of Sidabenamine in treating breast cancer
many tumors, including blood system tumors and solid tumors such as breast cancer, there are epigenetic abnormalitiesSidabenamine is a histone deacetylase inhibitor that treats lymphoma and the success of breast cancer is inextricably linked to its mechanism of actionSidabenamine has a nonspecific and breast cancer-specific dual anti-tumor mechanism First, it directly induces tumor cell cycle blocking and apoptosis, and slows and reverses epithelial cell-interstitial conversion, thereby inhibiting tumor metastasis Sidabenamine through epigenetic regulation, so that the original insensitive to the drug or the drug target is not fully exposed tumors re-sensitive to treatment In the development of tumor, microenvironment is very important, the preliminary basic research confirmed that the regulatory effect of Sidabenamine is mainly manifested in the regulation of the immune microenvironment, promote the activation of anti-tumor immune cells, increase antigen submission, reduce immunosuppressive cells, and also have inhibition effect on tumor stem cells There are epigenetic abnormalities in breast cancer, the most important reason for endocrine therapy resistance is the activation of growth factor signaling pathways, and sidabenamine has inhibition effect on growth factor signaling pathways At the same time, sidabenamine can improve the level of lysine acetylation of ER, directly inhibittherification of ligand dependence activation pathway Based on the above-mentioned mechanism of action, in the ACE study to recruit patients into the group, I personally very confident that the majority of the first 20 patients are in my center into the group, the fact also further proved that the efficacy of Sidabenamine is very good, less adverse reactions, patients can get a longer period of high quality of life condition relief With the appearance of efficacy and good tolerable feedback, patients also from initial doubt to recognition, the late ACE research progress is very smooth and finally achieved good results the future path of Sidabenamine is getting wider and wider
as China's original original new drug, Sidabenamine has been approved for lymphoma and breast cancer treatment, which is due to its excellent efficacy It is hoped that in the future Sidabenamine will also be able to conduct more clinical studies in other solid tumors and blood tumors to expand its application In addition, in the field of breast cancer treatment, ACE research supports sidabenamine is mainly used in endocrine drug treatment progress of patients, hope that with the progress of precision medical treatment, can further locate the more suitable population, while the clinical application of Sidabenamine further forward, the good medicine for earlier use of more suitable patients, which is not only in line with the needs of precision treatment of contemporary tumors, but also in line with the pursuit of doctors, but also to ensure the interests of patients I believe that as more clinical research data on Sidabenamine becomes available, more and better results will be achieved, bringing good news to the clinical treatment of more patients author: Zhang Qingxuan Source: of the Oncology Information